Caeregen Therapeutics, a regenerative medicine therapeutics company and Wacker Biotech, a contract development and manufacturing organization (CDMO), will collaborate on the development and production of CTR-107 (Noregen™), a novel regenerative therapeutic for the treatment of retinal-related vision loss. As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands, to support Phase I/II clinical study initiation in 2024. CTR-107 is the first program to obtain U.S. FDA Rare Pediatric Disease Designation for treatment of Familial Exudative Vitreoretinopathy (FEVR).
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!